Metastatic Cancer, Solid Tumors
Conditions
Keywords
Immunotherapy, Checkpoint Inhibitor, Vaccine, Combination Therapy, Metastatic Cancer
Brief summary
Background: Combination immunotherapy techniques are being explored to improve responses and enhance benefits in people with cancer. Researchers want to see if this type of treatment can help people with advanced solid tumors. Objective: To find a safe dose of SX-682 in combined treatment with Bintrafusp alfa and BN-CV301 vaccines and to see if this treatment will cause tumors to shrink. Eligibility: Adults age 18 and older with metastatic cancer may be eligible for the first part of the trial. Adults age 18 and older with metastatic triple negative breast cancer or p16 negative head and neck squamous cell cancer, and who are not candidates for curative surgery may be eligible for the second part of the trial. Design: Participants will be screened under a separate protocol. Participants may have tumor biopsies. They will have physical exams. Their symptoms and medicines will be reviewed. They will have blood tests. They will have electrocardiograms to evaluate their heart. Participants will have imaging scans of the chest, abdomen, and pelvis. They may have a procedure where a small tube with a tiny video camera is put into the nose to look at the throat if they have head and neck cancers. Participants will get bintrafusp alfa through an intravenous catheter. For this, a small tube is put into an arm vein. They will get BN-CV301 vaccines as injections in the arm or thigh. They will take SX-682 by mouth twice a day. They will take the study drugs up to 2 years. They will keep a medicine diary. Participants will have study visits every 2 weeks. They will have 1 or 2 follow-up visits within 30 days after they stop treatment. Then they will be monitored by phone or email for 2 years.
Detailed description
Background: * Combination immunotherapy approaches are being actively explored to further improve responses, enhance clinical benefit, and overcome resistance to Programmed Cell Death Ligand 1 (PD(L)-1) agents in cancer participants. * Interleukin-8 (IL-8) is a pro-inflammatory chemokine produced by various cell types. Overexpression of IL-8 and/or its receptors C-X-C motif chemokine receptor 1 (CXCR1) and C-X-C motif chemokine receptor 2 (CXCR2), is commonly seen in many human cancers including breast, cervical, melanoma and prostate. * SX-682 is an oral, small molecule inhibitor of the CXCR1/2 chemokine receptors that are believed involved in myeloid-derived suppressor cells (MDSC)-recruitment to tumor and other pro-tumoral mechanisms. * Bintrafusp alfa (M7824 or MSB0011359C) is a bifunctional protein composed of the extracellular domain of the Transforming Growth Factor Beta Receptor 2 (TGF-BetaRII) receptor (TGF-Beta 'trap') fused to a human immunoglobulin G1 (IgG1). Preclinical data shows bintrafusp alfa treatment increases T-cell trafficking, antigen specific cluster of differentiation 8 (CD8+) T-cell lysis and natural killer (NK) cell activation. * CV301 is a poxviral-based vaccine comprised of recombinant Modified vaccinia Ankara (MVA-BN-CV301, prime) and recombinant fowlpox (FPV-CV301, boost). CV301 contains transgenes encoding two (2) tumor-associated antigens (TAA), mucin 1 (MUC1) and carcinoembryonic antigen (CEA), as well as three costimulatory molecules (B7.1, intercellular adhesion molecule 1 (ICAM-1) and lymphocyte function-associated antigen 3 (LFA-3), designated TRICOM). A recent phase 1 clinical trial demonstrated that antigen-specific T cells to MUC1 and CEA, as well as to a cascade antigen, brachyury, were generated in most participants. * Preclinical studies performed in LTIB with SX-682, M7824 and a CEA-based vaccine showed a significant reduction in tumor growth as well as a significant increase in tumor infiltration with cluster of differentiation 4 (CD4+) and CD8+ T cells. Objectives: * Arm 1 (Sequential Dose Escalation): * To evaluate the safety and tolerability of single agent SX-682 given for 2 weeks preceding M7824 and CV301. * To determine the maximum tolerated dose (MTD) of SX-682 given for 2 weeks preceding M7824 and the CV301 vaccines in participants with advanced or metastatic solid tumors. If the MTD is not reached the study will be focused to describe the safety and tolerability of SX-682 followed by M7824 and CV301 vaccines. * Arm 2 (Combination Dose Escalation): --To determine the recommended phase 2 dose (RP2D) of SX-682 given concurrently with M7824 and the CV301 vaccines in participants with advanced or metastatic solid tumors. If the MTD is not reached the study will be focused to describe the safety and tolerability of the drug combination. * Arm 3 (Expansion): * To evaluate preliminary efficacy based on Objective Response Rate (ORR), in each disease separately in two cohorts: Triple Negative Breast Cancer (TNBC) and Human papilloma virus (HPV) negative head and neck squamous cell carcinoma (HNSCC). Eligibility: * Age \>= 18 years old * Arms 1 and 2 (Dose-Escalation Cohort): Subjects with cytologically or histologically confirmed locally advanced or metastatic solid tumors. * Arm 3 (Expansion Cohorts): * Triple Negative Breast Cancer (TNBC): Subjects with cytologically or histologically confirmed locally advanced or metastatic Triple Negative Breast Cancer that has progressed on at least one prior treatment in the advanced or in the metastatic setting. * Human papilloma virus (HPV) negative head and neck squamous cell carcinoma (HNSCC): Subjects with cytologically or histologically confirmed locally advanced or metastatic, HPV negative head and neck squamous cell cancer (p16 negative for oropharyngeal) that has progressed on at least one prior treatment involving a platinum drug or cetuximab in advanced or in the metastatic setting. * Prior first line systemic therapy is required unless there is no standard treatment available, the participant cannot tolerate standard first line treatment, or the participant declines standard treatment after appropriate counseling has been provided. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 * Adequate renal, hepatic, and hematologic function * Subjects in Arms 1 and 2 may have disease that is measurable or non-measurable but evaluable disease (e.g. present on bone scan, rising tumor markers, non-measurable by Response Evaluation Criteria in Solid Tumors (RECIST) but visible on computed tomography (CT) scan). Participants with third space fluid (for example pleural effusions) as only site of disease will not be eligible. Subjects in Arm 3 must have measurable disease according to RECIST 1.1 Design: * Arm 1 is a phase I, open-label, 3+3 sequential dose escalation trial with short term, 2-week SX-682 monotherapy, sequentially followed by treatment with M7824 and the CV301 vaccine series in advanced solid tumors (every 2 weeks (Q2W) dosing schedule) for the duration of treatment. * Arm 2 is a phase I, open-label, 3+3 combination dose escalation trial with concurrently administered SX-682, M7824 and CV301 in advanced solid tumors (Q2W dosing schedule). * Arm 3 has two expansion cohorts. Following identification of the MTD or recommended phase 2 dose (R2PD) for the combination of SX-682, M7824 and CV301 vaccine given concurrently, disease-specific phase 2 expansion cohorts will open in 1) advanced/metastatic triple negative breast cancer and 2) advanced/metastatic, platinum-refractory HPV negative head and neck squamous cell carcinoma.
Interventions
DRUGSX-682
SX-682 will be given orally at designated dose twice a day every day
DRUGM7824
Subjects will receive M7824 at a flat dose of 1,200 mg intravenously on Days 1 and 15 of each cycle.
BIOLOGICALMVA-BN-CV301
MVA-BN-CV301 will be given as four subcutaneous injections (4x10\^8 Inf.U/0.5ml twice during Cycle 1 (Days 1 and 15)
BIOLOGICALrecombinant fowlpox viral (FPV)-CV301
FPV-CV301 will be given as one subcutaneous injection (1x10\^9 Inf.U/0.5ml) on Day 1 starting at cycle 2 through cycle 5 (every 4 weeks) then on Day 1 of every 3 cycles (Cycles 8 and Cycle 11).
Sponsors
National Cancer Institute (NCI)
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* INCLUSION CRITERIA: * Participants must have histologically or cytologically confirmed: * Metastatic or locally advanced, Solid tumor (Cohort 1) OR --Metastatic or locally recurrent, non-resectable Triple Negative Breast Cancer (TNBC), defined as estrogen receptor (ER) \< 10%, progesterone receptor (PR) \< 10% per immunohistochemistry (IHC) and human epidermal growth factor receptor 2 (HER2) negative. HER2 negative or unamplified breast cancer is defined as IHC 0 or 1+ or IHC 2+ with FISH average HER2 copy number \< 4.0 signals per cell or HER2/chromosome 17 (CEP17) \< 2.0 with average HER2 copy number \< 4.0 signals per cell.\[89\] HER2 testing must have been performed in a laboratory accredited by the College of American Pathology (CAP) or another accrediting entity (Cohort 2). OR * Metastatic or locally recurrent, non-resectable p16 negative Head and Neck Squamous Cell Cancer (HNSCC). Oropharyngeal tumors must be negative for p16 overexpression by IHC per American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines and in a CAP accredited lab.\[90\] All other head and neck malignancies do not require p16 testing (Cohort 3). * Participants must have histologically or cytologically confirmed metastatic or locally advanced disease. Historical reports from a CAP accredited lab are acceptable. * Subjects in Arms 1 and 2 may have disease that is measurable or non-measurable but evaluable disease (e.g. present on bone scan, rising tumor markers, non-measurable by Response Evaluation Criteria in Solid Tumors (RECIST) but visible on computed tomography (CT) scan). Participants with third space fluid (for example pleural effusions) as only site of disease will not be eligible. Subjects in Arm 3 must have measurable disease according to RECIST 1.1 * Participants must * have received at least one prior systemic therapy for metastatic or locally advanced disease, unless there is no standard treatment available, OR --not tolerate standard first line treatment, OR --decline standard treatment after appropriate counseling has been provided. Note: Participants in Arm 3, Cohort 3 who have programmed death-ligand 1 (PD-L1) positive triple-negative breast cancer (TNBC) must have progressed on atezolizumab + nab-paclitaxel. Participants in Arm 3, Cohort 3 (p16 negative head and neck squamous cell carcinomas (HNSCC) must have progressed on or been intolerant to a regimen involving a platinum drug or cetuximab monotherapy. * Age greater than or equal to 18 years. * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1. * Participants must have adequate organ and marrow function as defined below: * Absolute neutrophil count (ANC) \>1,500/mcL * Platelets \>100,000/mcL * Hemoglobin \> 9 g/dL without a blood transfusion in the 14 days prior to enrollment. * Total bilirubin \< 1.5X upper limit of normal (ULN) OR in subjects with Gilbert s Syndrome, a total bilirubin \< 3.0 x ULN * Aspartate aminotransferase (AST) serum glutamic-oxaloacetic transaminase (SGOT)/alanine aminotransferase (ALT) serum glutamic-pyruvic aminotransaminase (SGPT) \<2.5 X institutional upper limit of normal OR in subjects with known liver metastasis, AST/ALT \< 3.0 X ULN * An estimated creatinine clearance (CrCl) \> 60 mL/min/1.73 m\^2 using the Cockcroft-Gault calculation (https://www.kidney.org/professionals/KDOQI/gfr\_calculatorCoc). * The effects of immunotherapies on the developing human fetus are unknown. For this reason and because immunotherapy agents as well as other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) at the time of study entry, for the duration of study treatment and up to 6 months after the last dose of the study drug (s). Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. * Participants with well-controlled human immunodeficiency virus (HIV) infection are eligible for trial as long as: * On an effective anti-retroviral therapy (ART) \> 4 weeks and with evidence of viral suppression defined as HIV viral load \< 400 copies/mL at enrollment * CD4+ count \> 200 cells/microL at enrollment * No reported opportunistic infections within 6 months prior to enrollment except for the following which will be allowed: * Esophageal candidiasis treated within last 6 months or currently improving with antifungal treatment * Oral and/or genital herpes simplex virus (HSV) treated within last 6 months or currently improving with antiviral treatment * Mycobacterium avium infection in last 6 months or that has been treated for at least 1month. * Immunomodulating drugs must be discontinued at least 1 weeks prior to enrollment for recent short course use (less than or equal to 14 days) or discontinued at least 4 weeks prior to enrollment for long term use (\> 14 days). * Participants must have a received their last treatment \> 4 weeks or 5 half-lives of the last treatment drug, whichever is shorter before starting on trial. * Participants with known history of hepatitis B (HBV) infection are eligible for trial as long as the HBV viral load is undetectable. * Patients with known history of hepatitis C (HCV) infection must have been treated and cured (viral load is undetectable). For participants with HCV infection who are currently on treatment, they are eligible if they have an undetectable or unquantifiable HCV ribonucleic acid (RNA) 12 weeks or longer after definitive treatment completion. * Subjects must be able to understand and be willing to sign a written informed consent document.
Exclusion criteria
* Participants who are receiving any other investigational agents. * Participants with active brain metastases or central nervous system metastasis (less than 28 days out from definitive radiotherapy or surgery of brain metastasis) are excluded from this clinical trial. However, patients with treated brain metastasis are eligible if there is no magnetic resonance imaging (MRI) evidence of progression for 6 weeks after treatment is complete and the MRI within 28 days prior to enrollment. Participants requiring immunosuppressive doses of systemic corticosteroids (\> 10 mg/day prednisone equivalent) for palliation are excluded. Patients with evidence of intratumoral or peritumoral brain metastasis hemorrhage on screening imaging are also excluded unless the hemorrhage of brain metastases is grade \< 1 and has been stable on two consecutive imaging scans. * History of allergic reactions attributed to compounds of similar chemical or biologic composition to any of study drugs * Steroid use or active autoimmune disease that might deteriorate when receiving an immunostimulatory agent with the exception of: * Diabetes type I, eczema, vitiligo, alopecia, psoriasis, hypo- or hyperthyroid disease or other mild autoimmune disorder not requiring immunosuppressive treatment; * Participants requiring hormone replacement with corticosteroid are eligible if the steroids are administered only for the purpose of adrenal insufficiency and at doses of \<10 mg of prednisone or equivalent per day; * Administration of steroids for other conditions through a route known to result in a minimal systemic exposure (topical, intranasal, intro-ocular, or inhalation) is acceptable; * Participants on physiologic doses of systemic intravenous or oral corticosteroid therapy (greater than or equal to the equivalent of prednisone 10 mg/day. * The use of corticosteroids as premedication for contrast-enhanced studies which is allowed prior to enrollment. * Participants with a history of serious intercurrent chronic or acute illness, such as cardiac or pulmonary disease, hepatic disease, bleeding diathesis or recent (within 3 months) clinically significant bleeding events or other illness considered by the Investigator as high risk for investigational drug treatment. * History of second malignancy within 3 years of enrollment except for the following: adequately treated localized skin cancer, ductal carcinoma in situ, cervical carcinoma in situ, superficial bladder cancer or other localized malignancy which has been adequately treated. * Receipt of any organ transplantation requiring ongoing immunosuppression including allogenic stem-cell transplant. * Participants with bone metastases who have initiated denosumab or a bisphosphonate therapy within 28 days prior to enrollment. Continuation of prior therapy is allowed. * Participants who have a corrected QT interval by Fridericia (QTcf) interval \> 475 msec or \> 480 msec with a bundle branch block (BBB) on screening electrocardiogram. * Participants with a personal or family history of long-QT syndrome or are on a concomitant drug that is known to cause significant QTc prolongation within 2 weeks or 5 half-lives (whichever is shorter) of enrollment * Participants with heart failure (New York Heart Association \[NYHA\] class III or IV) or cerebrovascular accident within one year or acute myocardial infarction within one year. * Participants unwilling to accept blood products or blood transfusions as medically indicated. As there is a risk of severe bleeding with M7824, participants must be willing to receive blood transfusions if medically necessary for their own safety * Any other condition, which would, in the opinion of the Principal Investigator indicated the subject is a poor candidate for the clinical trial or would jeopardize the subject or the integrity of the data obtained. * Pregnant women are excluded from this study because study drugs potential for teratogenic or abortifacient effects are unknown. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with study drugs, breastfeeding should be discontinued if the mother is treated with study drugs.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants Who Experience a Response | 11 months | The percentage of participants who experience a response will be reported along with 95% two-sided confidence intervals. The objective response is the best overall response recorded from the start of treatment until disease progression/recurrence per the Response Evaluation Criteria in Solid Tumors (RECIST). Complete Response is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters. Stable Disease is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of diameters while on study. Progressive Disease (PD) is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. |
| Dose Limiting Toxicities (DLT) | DLT observation period (first 4 weeks) | A DLT is defined as any one of the following adverse events (AEs), as defined by Common Terminology Criteria for Adverse Events (CTCAE v5.0), that is possibly attributable to study drugs by the Investigator, that occur within 28 days after the start of study therapy: Any Grade 4 (life threatening) AEs, except for example, laboratory values that are determined to not be clinically significant or single laboratory valued that resolve to Grade ≤ 1 or baseline grade within 7 days with adequate medical management. Average corrected QT interval by Fridericia (QTcF)≥ 501 msec or \> 60 msec change from baseline (Grade 3). Any Grade 3 (severe) AEs except for example, Grade 3 flu-like symptoms or fever, as well as associated symptoms of fatigue, headaches, nausea, emesis which can be controlled with conservative medical management. Any grade 3 or higher adverse event or unexpected toxicities due to the combination of therapies that would not be expected with individual agents alone. |
| Number of Participants With Grades 3-5 Adverse Events (AEs) Related and/or Unrelated to SX-682 + BinTrafusp Alfa (M7824) + BN-CV301 | Approximately 16 months and 11 days | Adverse events were assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). Grade 1 is mild. Grade 2 is moderate. Grade 3 is severe. Grade 4 is life-threatening. Grade 5 is death related to AE. |
| Maximum Tolerated Dose (MTD) of SX-682 Followed by BinTrafusp Alfa (M7824) and CV301 Vaccines in Participants With Advanced or Metastatic Solid Tumors. | Period of Safety lead-in (monotherapy), approximately 28 days | The MTD is the dose at which no more than 1 of 6 subjects taking SX-682 followed by M7824 and CV301 vaccines experience a dose-limiting toxicity (DLT). A DLT is defined as any one of the following adverse events (AEs), as defined by Common Terminology Criteria for Adverse Events (CTCAE v5.0), that is possibly attributable to study drugs by the Investigator, that occur within 28 days after the start of study therapy. |
| Recommended Phase II Dose (RP2D) of SX-682 With BinTrafusp Alfa (M7824) and CV301 Vaccines in Participants With Advanced or Metastatic Solid Tumors. | Approximately 28 days | Recommended phase II dose is defined as the dose defined in the phase I portion of a study that will be administered to participants on the phase II portion. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants Disease Control Rate (DCR): Complete Response (CR)+ Partial Response (PR) + Stable Disease (SD) | Date first participant enrolled and ending on the off treatment date of the last participant on treatment (i.e., assessed beyond the primary completion date), approximately 15 months and 14 days. | The percentage of participants disease control rate (DCR): Complete response (CR)+ partial response (PR) + stable disease (SD) was measured by the Response Evaluation Criteria in Solid Tumors (RECIST). Complete Response is disappearance of all target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters. Stable Disease is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of diameters while on study. Progressive Disease (PD) is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). |
| Progression-free Survival (PFS) Using Response Evaluation Criteria in Solid Tumors (RECIST)1.1. | Time from start of treatment to time of progression or death, whichever occurs first, approximately 10 months | PFS is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first. Progression per the RECIST is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). The appearance of one or more new lesions is also considered progressions. |
| Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Predose, 30 minutes, 60 minutes, 120 minutes, <6 hours of 2nd dose, and end of infusion (EOI) | Plasma and serum samples will be drawn and may be analyzed by a validated immunoassay to quantitate SX-682 as a single agent and in combination or by a validated electrochemiluminescence immunoassay to detect the presence of M7824 concentration. |
| Pharmacodynamic Profile of SX-682 as a Single Agent and in Combination | Predose, 30 minutes, 60 minutes, 120 minutes, <6 hours of 2nd dose, and end of infusion (EOI) | Plasma and serum samples will be drawn and may be analyzed by a validated immunoassay to quantitate SX-682 as a single agent and in combination or by a validated electrochemiluminescence immunoassay to detect the presence of M7824 concentration. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0) | Date treatment consent signed to date off study, approximately 5 months and 9 days, 13 months and 17 days, and 6 months and 1 day for DL1, DL2, and DL3 respectively. Adverse events were assessed beyond the primary completion date. | Here is the number of participants with serious and/or non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. |
Countries
United States
Participant flow
Pre-assignment details
The trial never reached the point of enrolling to phase 2. It stopped early before maximum tolerated dose (MTD) was reached.
Participants by arm
| Arm | Count |
|---|---|
| Phase I Dose Level 1(DL1) 25mg SX-682 Monotherapy Sequentially Foll/by 1200mg BinTraFusp Alfa +CV301 Participants with any solid tumor will receive a 2- week monotherapy lead-in of SX-682 DL2 25 mg by mouth (PO) twice a day (BID) followed sequentially by treatment with a dual combination of + BinTrafusp Alfa (M7824) 1200 mg fixed dose intravenous (IV) + BN-CV301.
Participants will be evaluated for dose-limiting toxicities at the completion of the dose level before enrollment to the next dose level begins | 3 |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 Participants with any solid tumor will receive a 2- week monotherapy lead-in of SX-682 DL2 50 mg by mouth (PO) twice a day (BID) followed sequentially by treatment with a dual combination of + BinTrafusp Alfa (M7824) 1200 mg fixed dose intravenous (IV) + BN-CV301.
Participants will be evaluated for dose-limiting toxicities at the completion of the dose level before enrollment to the next dose level begins | 6 |
| Phase I Dose Level 3 (DL3) 100 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa +CV301 Participants with any solid tumor will receive a 2- week monotherapy lead-in of SX-682 DL1 100 mg by mouth (PO) twice a day (BID) followed sequentially by treatment with a dual combination of + BinTrafusp Alfa (M7824) 1200 mg fixed dose intravenous (IV) + BN-CV301.
Participants will be evaluated for dose-limiting toxicities at the completion of the dose level before enrolling onto the next dose level. | 3 |
| Total | 12 |
Baseline characteristics
| Characteristic | Phase I Dose Level 1(DL1) 25mg SX-682 Monotherapy Sequentially Foll/by 1200mg BinTraFusp Alfa +CV301 | Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Phase I Dose Level 3 (DL3) 100 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa +CV301 | Total |
|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 1 Participants | 1 Participants | 1 Participants | 3 Participants |
| Age, Categorical Between 18 and 65 years | 2 Participants | 5 Participants | 2 Participants | 9 Participants |
| Age, Continuous | 61.53 years STANDARD_DEVIATION 5.23 | 59.38 years STANDARD_DEVIATION 6.08 | 54 years STANDARD_DEVIATION 13.29 | 58.58 years STANDARD_DEVIATION 7.89 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 1 Participants | 0 Participants | 1 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 3 Participants | 5 Participants | 3 Participants | 11 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 1 Participants | 1 Participants | 1 Participants | 3 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 2 Participants | 5 Participants | 2 Participants | 9 Participants |
| Region of Enrollment United States | 3 participants | 6 participants | 3 participants | 12 participants |
| Sex: Female, Male Female | 1 Participants | 2 Participants | 2 Participants | 5 Participants |
| Sex: Female, Male Male | 2 Participants | 4 Participants | 1 Participants | 7 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 1 / 3 | 3 / 6 | 2 / 3 |
| other Total, other adverse events | 3 / 3 | 6 / 6 | 3 / 3 |
| serious Total, serious adverse events | 1 / 3 | 3 / 6 | 1 / 3 |
Outcome results
Primary
Dose Limiting Toxicities (DLT)
A DLT is defined as any one of the following adverse events (AEs), as defined by Common Terminology Criteria for Adverse Events (CTCAE v5.0), that is possibly attributable to study drugs by the Investigator, that occur within 28 days after the start of study therapy: Any Grade 4 (life threatening) AEs, except for example, laboratory values that are determined to not be clinically significant or single laboratory valued that resolve to Grade ≤ 1 or baseline grade within 7 days with adequate medical management. Average corrected QT interval by Fridericia (QTcF)≥ 501 msec or \> 60 msec change from baseline (Grade 3). Any Grade 3 (severe) AEs except for example, Grade 3 flu-like symptoms or fever, as well as associated symptoms of fatigue, headaches, nausea, emesis which can be controlled with conservative medical management. Any grade 3 or higher adverse event or unexpected toxicities due to the combination of therapies that would not be expected with individual agents alone.
Time frame: DLT observation period (first 4 weeks)
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Phase I Dose Level 1(DL1) 25mg SX-682 Monotherapy Sequentially Foll/by 1200mg BinTraFusp Alfa +CV301 | Dose Limiting Toxicities (DLT) | 0 toxicities |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Dose Limiting Toxicities (DLT) | 1 toxicities |
| Phase I Dose Level 3 (DL3) 100 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa +CV301 | Dose Limiting Toxicities (DLT) | 0 toxicities |
Primary
Maximum Tolerated Dose (MTD) of SX-682 Followed by BinTrafusp Alfa (M7824) and CV301 Vaccines in Participants With Advanced or Metastatic Solid Tumors.
The MTD is the dose at which no more than 1 of 6 subjects taking SX-682 followed by M7824 and CV301 vaccines experience a dose-limiting toxicity (DLT). A DLT is defined as any one of the following adverse events (AEs), as defined by Common Terminology Criteria for Adverse Events (CTCAE v5.0), that is possibly attributable to study drugs by the Investigator, that occur within 28 days after the start of study therapy.
Time frame: Period of Safety lead-in (monotherapy), approximately 28 days
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Phase I Dose Level 1(DL1) 25mg SX-682 Monotherapy Sequentially Foll/by 1200mg BinTraFusp Alfa +CV301 | Maximum Tolerated Dose (MTD) of SX-682 Followed by BinTrafusp Alfa (M7824) and CV301 Vaccines in Participants With Advanced or Metastatic Solid Tumors. | NA mg |
Primary
Number of Participants With Grades 3-5 Adverse Events (AEs) Related and/or Unrelated to SX-682 + BinTrafusp Alfa (M7824) + BN-CV301
Adverse events were assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). Grade 1 is mild. Grade 2 is moderate. Grade 3 is severe. Grade 4 is life-threatening. Grade 5 is death related to AE.
Time frame: Approximately 16 months and 11 days
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Phase I Dose Level 1(DL1) 25mg SX-682 Monotherapy Sequentially Foll/by 1200mg BinTraFusp Alfa +CV301 | Number of Participants With Grades 3-5 Adverse Events (AEs) Related and/or Unrelated to SX-682 + BinTrafusp Alfa (M7824) + BN-CV301 | Grade 5 Unrelated | 0 Participants |
| Phase I Dose Level 1(DL1) 25mg SX-682 Monotherapy Sequentially Foll/by 1200mg BinTraFusp Alfa +CV301 | Number of Participants With Grades 3-5 Adverse Events (AEs) Related and/or Unrelated to SX-682 + BinTrafusp Alfa (M7824) + BN-CV301 | Grade 3 Related | 2 Participants |
| Phase I Dose Level 1(DL1) 25mg SX-682 Monotherapy Sequentially Foll/by 1200mg BinTraFusp Alfa +CV301 | Number of Participants With Grades 3-5 Adverse Events (AEs) Related and/or Unrelated to SX-682 + BinTrafusp Alfa (M7824) + BN-CV301 | Grade 5 Related | 0 Participants |
| Phase I Dose Level 1(DL1) 25mg SX-682 Monotherapy Sequentially Foll/by 1200mg BinTraFusp Alfa +CV301 | Number of Participants With Grades 3-5 Adverse Events (AEs) Related and/or Unrelated to SX-682 + BinTrafusp Alfa (M7824) + BN-CV301 | Grade 4 Unrelated | 0 Participants |
| Phase I Dose Level 1(DL1) 25mg SX-682 Monotherapy Sequentially Foll/by 1200mg BinTraFusp Alfa +CV301 | Number of Participants With Grades 3-5 Adverse Events (AEs) Related and/or Unrelated to SX-682 + BinTrafusp Alfa (M7824) + BN-CV301 | Grade 4 Related | 0 Participants |
| Phase I Dose Level 1(DL1) 25mg SX-682 Monotherapy Sequentially Foll/by 1200mg BinTraFusp Alfa +CV301 | Number of Participants With Grades 3-5 Adverse Events (AEs) Related and/or Unrelated to SX-682 + BinTrafusp Alfa (M7824) + BN-CV301 | Grade 3 Unrelated | 1 Participants |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Number of Participants With Grades 3-5 Adverse Events (AEs) Related and/or Unrelated to SX-682 + BinTrafusp Alfa (M7824) + BN-CV301 | Grade 4 Related | 0 Participants |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Number of Participants With Grades 3-5 Adverse Events (AEs) Related and/or Unrelated to SX-682 + BinTrafusp Alfa (M7824) + BN-CV301 | Grade 4 Unrelated | 0 Participants |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Number of Participants With Grades 3-5 Adverse Events (AEs) Related and/or Unrelated to SX-682 + BinTrafusp Alfa (M7824) + BN-CV301 | Grade 5 Unrelated | 1 Participants |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Number of Participants With Grades 3-5 Adverse Events (AEs) Related and/or Unrelated to SX-682 + BinTrafusp Alfa (M7824) + BN-CV301 | Grade 3 Unrelated | 4 Participants |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Number of Participants With Grades 3-5 Adverse Events (AEs) Related and/or Unrelated to SX-682 + BinTrafusp Alfa (M7824) + BN-CV301 | Grade 5 Related | 0 Participants |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Number of Participants With Grades 3-5 Adverse Events (AEs) Related and/or Unrelated to SX-682 + BinTrafusp Alfa (M7824) + BN-CV301 | Grade 3 Related | 2 Participants |
| Phase I Dose Level 3 (DL3) 100 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa +CV301 | Number of Participants With Grades 3-5 Adverse Events (AEs) Related and/or Unrelated to SX-682 + BinTrafusp Alfa (M7824) + BN-CV301 | Grade 5 Unrelated | 0 Participants |
| Phase I Dose Level 3 (DL3) 100 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa +CV301 | Number of Participants With Grades 3-5 Adverse Events (AEs) Related and/or Unrelated to SX-682 + BinTrafusp Alfa (M7824) + BN-CV301 | Grade 3 Related | 2 Participants |
| Phase I Dose Level 3 (DL3) 100 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa +CV301 | Number of Participants With Grades 3-5 Adverse Events (AEs) Related and/or Unrelated to SX-682 + BinTrafusp Alfa (M7824) + BN-CV301 | Grade 4 Related | 0 Participants |
| Phase I Dose Level 3 (DL3) 100 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa +CV301 | Number of Participants With Grades 3-5 Adverse Events (AEs) Related and/or Unrelated to SX-682 + BinTrafusp Alfa (M7824) + BN-CV301 | Grade 5 Related | 0 Participants |
| Phase I Dose Level 3 (DL3) 100 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa +CV301 | Number of Participants With Grades 3-5 Adverse Events (AEs) Related and/or Unrelated to SX-682 + BinTrafusp Alfa (M7824) + BN-CV301 | Grade 4 Unrelated | 0 Participants |
| Phase I Dose Level 3 (DL3) 100 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa +CV301 | Number of Participants With Grades 3-5 Adverse Events (AEs) Related and/or Unrelated to SX-682 + BinTrafusp Alfa (M7824) + BN-CV301 | Grade 3 Unrelated | 2 Participants |
Primary
Percentage of Participants Who Experience a Response
The percentage of participants who experience a response will be reported along with 95% two-sided confidence intervals. The objective response is the best overall response recorded from the start of treatment until disease progression/recurrence per the Response Evaluation Criteria in Solid Tumors (RECIST). Complete Response is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters. Stable Disease is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of diameters while on study. Progressive Disease (PD) is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study.
Time frame: 11 months
Population: 2 participants were not evaluable for this outcome measure.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Phase I Dose Level 1(DL1) 25mg SX-682 Monotherapy Sequentially Foll/by 1200mg BinTraFusp Alfa +CV301 | Percentage of Participants Who Experience a Response | Stable Disease | 100 percentage of participants |
| Phase I Dose Level 1(DL1) 25mg SX-682 Monotherapy Sequentially Foll/by 1200mg BinTraFusp Alfa +CV301 | Percentage of Participants Who Experience a Response | Complete Response | 0 percentage of participants |
| Phase I Dose Level 1(DL1) 25mg SX-682 Monotherapy Sequentially Foll/by 1200mg BinTraFusp Alfa +CV301 | Percentage of Participants Who Experience a Response | Progressive Disease | 100 percentage of participants |
| Phase I Dose Level 1(DL1) 25mg SX-682 Monotherapy Sequentially Foll/by 1200mg BinTraFusp Alfa +CV301 | Percentage of Participants Who Experience a Response | Partial Response | 0 percentage of participants |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Percentage of Participants Who Experience a Response | Stable Disease | 60 percentage of participants |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Percentage of Participants Who Experience a Response | Partial Response | 0 percentage of participants |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Percentage of Participants Who Experience a Response | Complete Response | 0 percentage of participants |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Percentage of Participants Who Experience a Response | Progressive Disease | 40 percentage of participants |
| Phase I Dose Level 3 (DL3) 100 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa +CV301 | Percentage of Participants Who Experience a Response | Partial Response | 0 percentage of participants |
| Phase I Dose Level 3 (DL3) 100 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa +CV301 | Percentage of Participants Who Experience a Response | Complete Response | 0 percentage of participants |
| Phase I Dose Level 3 (DL3) 100 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa +CV301 | Percentage of Participants Who Experience a Response | Progressive Disease | 100 percentage of participants |
| Phase I Dose Level 3 (DL3) 100 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa +CV301 | Percentage of Participants Who Experience a Response | Stable Disease | 0 percentage of participants |
Primary
Recommended Phase II Dose (RP2D) of SX-682 With BinTrafusp Alfa (M7824) and CV301 Vaccines in Participants With Advanced or Metastatic Solid Tumors.
Recommended phase II dose is defined as the dose defined in the phase I portion of a study that will be administered to participants on the phase II portion.
Time frame: Approximately 28 days
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Phase I Dose Level 1(DL1) 25mg SX-682 Monotherapy Sequentially Foll/by 1200mg BinTraFusp Alfa +CV301 | Recommended Phase II Dose (RP2D) of SX-682 With BinTrafusp Alfa (M7824) and CV301 Vaccines in Participants With Advanced or Metastatic Solid Tumors. | NA mg |
Secondary
Percentage of Participants Disease Control Rate (DCR): Complete Response (CR)+ Partial Response (PR) + Stable Disease (SD)
The percentage of participants disease control rate (DCR): Complete response (CR)+ partial response (PR) + stable disease (SD) was measured by the Response Evaluation Criteria in Solid Tumors (RECIST). Complete Response is disappearance of all target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters. Stable Disease is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of diameters while on study. Progressive Disease (PD) is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study).
Time frame: Date first participant enrolled and ending on the off treatment date of the last participant on treatment (i.e., assessed beyond the primary completion date), approximately 15 months and 14 days.
Population: 2 participants were not evaluable for this outcome measure. The Rows were not planned to be mutually exhaustive and consisted of only those participants with response.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Phase I Dose Level 1(DL1) 25mg SX-682 Monotherapy Sequentially Foll/by 1200mg BinTraFusp Alfa +CV301 | Percentage of Participants Disease Control Rate (DCR): Complete Response (CR)+ Partial Response (PR) + Stable Disease (SD) | Partial Response | 0 percentage of participants |
| Phase I Dose Level 1(DL1) 25mg SX-682 Monotherapy Sequentially Foll/by 1200mg BinTraFusp Alfa +CV301 | Percentage of Participants Disease Control Rate (DCR): Complete Response (CR)+ Partial Response (PR) + Stable Disease (SD) | Complete Response | 0 percentage of participants |
| Phase I Dose Level 1(DL1) 25mg SX-682 Monotherapy Sequentially Foll/by 1200mg BinTraFusp Alfa +CV301 | Percentage of Participants Disease Control Rate (DCR): Complete Response (CR)+ Partial Response (PR) + Stable Disease (SD) | Stable Disease | 100 percentage of participants |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Percentage of Participants Disease Control Rate (DCR): Complete Response (CR)+ Partial Response (PR) + Stable Disease (SD) | Partial Response | 0 percentage of participants |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Percentage of Participants Disease Control Rate (DCR): Complete Response (CR)+ Partial Response (PR) + Stable Disease (SD) | Complete Response | 0 percentage of participants |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Percentage of Participants Disease Control Rate (DCR): Complete Response (CR)+ Partial Response (PR) + Stable Disease (SD) | Stable Disease | 60 percentage of participants |
| Phase I Dose Level 3 (DL3) 100 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa +CV301 | Percentage of Participants Disease Control Rate (DCR): Complete Response (CR)+ Partial Response (PR) + Stable Disease (SD) | Complete Response | 0 percentage of participants |
| Phase I Dose Level 3 (DL3) 100 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa +CV301 | Percentage of Participants Disease Control Rate (DCR): Complete Response (CR)+ Partial Response (PR) + Stable Disease (SD) | Stable Disease | 0 percentage of participants |
| Phase I Dose Level 3 (DL3) 100 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa +CV301 | Percentage of Participants Disease Control Rate (DCR): Complete Response (CR)+ Partial Response (PR) + Stable Disease (SD) | Partial Response | 0 percentage of participants |
Secondary
Pharmacodynamic Profile of SX-682 as a Single Agent and in Combination
Plasma and serum samples will be drawn and may be analyzed by a validated immunoassay to quantitate SX-682 as a single agent and in combination or by a validated electrochemiluminescence immunoassay to detect the presence of M7824 concentration.
Time frame: Predose, 30 minutes, 60 minutes, 120 minutes, <6 hours of 2nd dose, and end of infusion (EOI)
Population: No blood samples were collected because the study was closed prior to enrollment of any participants who would have received combination. Early closure was due to a safety stopping rule pre-specified in the protocol. Since no participants received SX-682 treatment in combination, with bintrasfusp alfa and CV-301, PK analysis cannot be performed as outlined in the study objectives. We cannot assess this endpoint without samples from participants treated with SX-682 + bintrasfusp alfa and CV-301.
Secondary
Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination
Plasma and serum samples will be drawn and may be analyzed by a validated immunoassay to quantitate SX-682 as a single agent and in combination or by a validated electrochemiluminescence immunoassay to detect the presence of M7824 concentration.
Time frame: Predose, 30 minutes, 60 minutes, 120 minutes, <6 hours of 2nd dose, and end of infusion (EOI)
Population: Blood samples were collected on only a subset of participants because the study was closed to enrollment early due to a safety stopping rule pre-specified in the protocol. Since no participants received SX-682 treatment in combination, with bintrasfusp alfa and CV-301, the PK analysis cannot be performed completely as outlined in the study objectives. Below are analyses of all available participant samples.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Phase I Dose Level 1(DL1) 25mg SX-682 Monotherapy Sequentially Foll/by 1200mg BinTraFusp Alfa +CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 3 - 30 minutes, Day 14 | NA ng/ml |
| Phase I Dose Level 1(DL1) 25mg SX-682 Monotherapy Sequentially Foll/by 1200mg BinTraFusp Alfa +CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 3 - 60 minutes, Day 14 | 6.13 ng/ml |
| Phase I Dose Level 1(DL1) 25mg SX-682 Monotherapy Sequentially Foll/by 1200mg BinTraFusp Alfa +CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 3 - 120 minutes, Day 14 | 31.3 ng/ml |
| Phase I Dose Level 1(DL1) 25mg SX-682 Monotherapy Sequentially Foll/by 1200mg BinTraFusp Alfa +CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 3 - 180 minutes, Day 14 | 65.6 ng/ml |
| Phase I Dose Level 1(DL1) 25mg SX-682 Monotherapy Sequentially Foll/by 1200mg BinTraFusp Alfa +CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 3- <6 hours (HR) of 2nd dose, Day 14 | 99.7 ng/ml |
| Phase I Dose Level 1(DL1) 25mg SX-682 Monotherapy Sequentially Foll/by 1200mg BinTraFusp Alfa +CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 3 - PRE, Day 7 | 53.7 ng/ml |
| Phase I Dose Level 1(DL1) 25mg SX-682 Monotherapy Sequentially Foll/by 1200mg BinTraFusp Alfa +CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 3 - 30 minutes, Day 7 | 51.2 ng/ml |
| Phase I Dose Level 1(DL1) 25mg SX-682 Monotherapy Sequentially Foll/by 1200mg BinTraFusp Alfa +CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 3 - PRE, Cycle 1 Day 1 (C1D1) | 170 ng/ml |
| Phase I Dose Level 1(DL1) 25mg SX-682 Monotherapy Sequentially Foll/by 1200mg BinTraFusp Alfa +CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 3 - End of infusion (EOI), C1D1 | 84 ng/ml |
| Phase I Dose Level 1(DL1) 25mg SX-682 Monotherapy Sequentially Foll/by 1200mg BinTraFusp Alfa +CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 3 - PRE, Cycle 2 Day 1 (C2D1) | NA ng/ml |
| Phase I Dose Level 1(DL1) 25mg SX-682 Monotherapy Sequentially Foll/by 1200mg BinTraFusp Alfa +CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 3 - PRE, Cycle 1 Day 15 (C1D15) | NA ng/ml |
| Phase I Dose Level 1(DL1) 25mg SX-682 Monotherapy Sequentially Foll/by 1200mg BinTraFusp Alfa +CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 1 - PRE, Day 7 | 214 ng/ml |
| Phase I Dose Level 1(DL1) 25mg SX-682 Monotherapy Sequentially Foll/by 1200mg BinTraFusp Alfa +CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 1 - PRE, Day 14 | NA ng/ml |
| Phase I Dose Level 1(DL1) 25mg SX-682 Monotherapy Sequentially Foll/by 1200mg BinTraFusp Alfa +CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 1 - 30 minutes, Day 14 | 7.88 ng/ml |
| Phase I Dose Level 1(DL1) 25mg SX-682 Monotherapy Sequentially Foll/by 1200mg BinTraFusp Alfa +CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 1 - 60 minutes, Day 14 | 17.7 ng/ml |
| Phase I Dose Level 1(DL1) 25mg SX-682 Monotherapy Sequentially Foll/by 1200mg BinTraFusp Alfa +CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 1 - 120 minutes, Day 14 | 104 ng/ml |
| Phase I Dose Level 1(DL1) 25mg SX-682 Monotherapy Sequentially Foll/by 1200mg BinTraFusp Alfa +CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 1 - 180 minutes, Day 14 | 124 ng/ml |
| Phase I Dose Level 1(DL1) 25mg SX-682 Monotherapy Sequentially Foll/by 1200mg BinTraFusp Alfa +CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 1 - <6 hours (HR) of 2nd dose, Day 14 | 105 ng/ml |
| Phase I Dose Level 1(DL1) 25mg SX-682 Monotherapy Sequentially Foll/by 1200mg BinTraFusp Alfa +CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 1 - 30 minutes, Day 7 | 193 ng/ml |
| Phase I Dose Level 1(DL1) 25mg SX-682 Monotherapy Sequentially Foll/by 1200mg BinTraFusp Alfa +CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 1 - PRE, Cycle 1 Day 1 (C1D1) | 325 ng/ml |
| Phase I Dose Level 1(DL1) 25mg SX-682 Monotherapy Sequentially Foll/by 1200mg BinTraFusp Alfa +CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 1 - End of infusion (EOI), C1D1 | 116 ng/ml |
| Phase I Dose Level 1(DL1) 25mg SX-682 Monotherapy Sequentially Foll/by 1200mg BinTraFusp Alfa +CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 1 - PRE, Cycle 1 Day 15 (C1D15) | NA ng/ml |
| Phase I Dose Level 1(DL1) 25mg SX-682 Monotherapy Sequentially Foll/by 1200mg BinTraFusp Alfa +CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 1 - PRE, Cycle 2 Day 1 (C2D1) | NA ng/ml |
| Phase I Dose Level 1(DL1) 25mg SX-682 Monotherapy Sequentially Foll/by 1200mg BinTraFusp Alfa +CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 2 - PRE, Day 14 | NA ng/ml |
| Phase I Dose Level 1(DL1) 25mg SX-682 Monotherapy Sequentially Foll/by 1200mg BinTraFusp Alfa +CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 2 - 30 minutes, Day 14 | 216 ng/ml |
| Phase I Dose Level 1(DL1) 25mg SX-682 Monotherapy Sequentially Foll/by 1200mg BinTraFusp Alfa +CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 2 - 60 minutes, Day 14 | 460 ng/ml |
| Phase I Dose Level 1(DL1) 25mg SX-682 Monotherapy Sequentially Foll/by 1200mg BinTraFusp Alfa +CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 2 - 120 minutes, Day 14 | 483 ng/ml |
| Phase I Dose Level 1(DL1) 25mg SX-682 Monotherapy Sequentially Foll/by 1200mg BinTraFusp Alfa +CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 2 - 180 minutes, Day 14 | 448 ng/ml |
| Phase I Dose Level 1(DL1) 25mg SX-682 Monotherapy Sequentially Foll/by 1200mg BinTraFusp Alfa +CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 2 - <6 hours (HR) of 2nd dose, Day 14 | 184 ng/ml |
| Phase I Dose Level 1(DL1) 25mg SX-682 Monotherapy Sequentially Foll/by 1200mg BinTraFusp Alfa +CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 2 - PRE, Day 7 | 421 ng/ml |
| Phase I Dose Level 1(DL1) 25mg SX-682 Monotherapy Sequentially Foll/by 1200mg BinTraFusp Alfa +CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 2 - 30 minutes, Day 7 | 394 ng/ml |
| Phase I Dose Level 1(DL1) 25mg SX-682 Monotherapy Sequentially Foll/by 1200mg BinTraFusp Alfa +CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 3 - PRE, Cycle 3 Day 1 (C3D1) | NA ng/ml |
| Phase I Dose Level 1(DL1) 25mg SX-682 Monotherapy Sequentially Foll/by 1200mg BinTraFusp Alfa +CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 2 - PRE, Cycle 1 Day 1 (C1D1) | 778 ng/ml |
| Phase I Dose Level 1(DL1) 25mg SX-682 Monotherapy Sequentially Foll/by 1200mg BinTraFusp Alfa +CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 2 - End of infusion (EOI), C1D1 | 587 ng/ml |
| Phase I Dose Level 1(DL1) 25mg SX-682 Monotherapy Sequentially Foll/by 1200mg BinTraFusp Alfa +CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 2 - PRE, Cycle 1 Day 15 (C1D15) | 1.24 ng/ml |
| Phase I Dose Level 1(DL1) 25mg SX-682 Monotherapy Sequentially Foll/by 1200mg BinTraFusp Alfa +CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 3 - PRE, Day 14 | NA ng/ml |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 7 - End of infusion (EOI), C1D1 | 1070 ng/ml |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 6 - PRE, Cycle 1 Day 1 (C1D1) | 683 ng/ml |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 6 - End of infusion (EOI), C1D1 | 429 ng/ml |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 7 - 30 minutes, Day 14 | 97.1 ng/ml |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 7 - 60 minutes, Day 14 | 110 ng/ml |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 7 - 120 minutes, Day 14 | 54.2 ng/ml |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 9 - 60 minutes, Day 14 | 37.9 ng/ml |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 4 - PRE, Day 7 | 710 ng/ml |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 9 - PRE, Day 14 | NA ng/ml |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 6 - 30 minutes, Day 7 | 777 ng/ml |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 6 - PRE, Cycle 1 Day 15 (C1D15) | 1.25 ng/ml |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 6 - PRE, Cycle 2 Day 1 (C2D1) | NA ng/ml |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 6 - PRE, Cycle 3 Day 1 (C3D1) | NA ng/ml |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 7 - PRE, Day 14 | NA ng/ml |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 7 - 180 minutes, Day 14 | 705 ng/ml |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 7 - <6 hours (HR) of 2nd dose, Day 14 | 489 ng/ml |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 7 - PRE, Day 7 | 1900 ng/ml |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 7 - 30 minutes, Day 7 | 1870 ng/ml |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 7 - PRE, Cycle 1 Day 1 (C1D1) | 1840 ng/ml |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 8 - PRE, Day 14 | NA ng/ml |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 8 - 30 minutes, Day 14 | 8.68 ng/ml |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 8 - 60 minutes, Day 14 | 394 ng/ml |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 8 - 120 minutes, Day 14 | 467 ng/ml |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 8 - 180 minutes, Day 14 | 443 ng/ml |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 8 - <6 hours (HR) of 2nd dose, Day 14 | 199 ng/ml |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 8 - PRE, Day 7 | 480 ng/ml |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 8 - 30 minutes, Day 7 | 455 ng/ml |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 8 - PRE, Cycle 1 Day 1 (C1D1) | 465 ng/ml |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 8 - End of infusion (EOI), C1D1 | 478 ng/ml |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 8 - PRE, Cycle 1 Day 15 (C1D15) | 1.54 ng/ml |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 8 - PRE, Cycle 2 Day 1 (C2D1) | NA ng/ml |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 8 - PRE, Cycle 3 Day 1 (C3D1) | NA ng/ml |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 9 - 30 minutes, Day 14 | 2.63 ng/ml |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 9 - 120 minutes, Day 14 | 113 ng/ml |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 9 - 180 minutes, Day 14 | 305 ng/ml |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 9 - <6 hours (HR) of 2nd dose, Day 14 | 350 ng/ml |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 9 - PRE, Cycle 1 Day 1 (C1D1) | 424 ng/ml |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 9 - End of infusion (EOI), C1D1 | 416 ng/ml |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 9 - PRE, Cycle 1 Day 15 (C1D15) | NA ng/ml |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 9 - PRE, Cycle 2 Day 1 (C2D1) | NA ng/ml |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 9 - Cycle 3 Day 1 (C3D1) | NA ng/ml |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 9 - PRE, Cycle 3 Day 1 (C3D1) | NA ng/ml |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 4 - PRE, Day 14 | NA ng/ml |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 4 - 30 minutes, Day 14 | 10.9 ng/ml |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 4 - 60 minutes, Day 14 | 38.2 ng/ml |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 4 - 120 minutes, Day 14 | 148 ng/ml |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 4 - 180 minutes, Day 14 | 160 ng/ml |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 4 - <6 hours (HR) of 2nd dose, Day 14 | 225 ng/ml |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 4 - 30 minutes, Day 7 | 827 ng/ml |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 4 - PRE, Cycle 1 Day 1 (C1D1) | 902 ng/ml |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 4 - End of infusion (EOI), C1D1 | 501 ng/ml |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 4 - PRE, Cycle 1 Day 15 (C1D15) | 1.56 ng/ml |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 4 - End of treatment (EOT), Cycle 2 Day 1 (C2D1) | NA ng/ml |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 5 - PRE, Day 14 | NA ng/ml |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 5 - 30 minutes, Day 14 | 11.9 ng/ml |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 5 - 60 minutes, Day 14 | 27.4 ng/ml |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 5 - 120 minutes, Day 14 | 439 ng/ml |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 5 - 180 minutes, Day 14 | 706 ng/ml |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 5 - <6 hours (HR) of 2nd dose, Day 14 | 419 ng/ml |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 5 - PRE, Day 7 | 1660 ng/ml |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 5 - 30 minutes, Day 7 | 1940 ng/ml |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 5 - PRE, Cycle 1 Day 1 (C1D1) | 3170 ng/ml |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 5 - End of infusion (EOI), C1D1 | 1660 ng/ml |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 6 - PRE, Day 14 | NA ng/ml |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 6 - 30 minutes, Day 14 | 32 ng/ml |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 6 - 60 minutes, Day 14 | 219 ng/ml |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 6 - 120 minutes, Day 14 | 395 ng/ml |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 6 - 180 minutes, Day 14 | 341 ng/ml |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 6 - <6 hours (HR) of 2nd dose, Day 14 | 260 ng/ml |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 6 - PRE, Day 7 | 679 ng/ml |
| Phase I Dose Level 3 (DL3) 100 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa +CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 12 - End of infusion (EOI), C1D1 | 6320 ng/ml |
| Phase I Dose Level 3 (DL3) 100 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa +CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 12 - PRE, Cycle 1 Day 1 (C1D1) | 7120 ng/ml |
| Phase I Dose Level 3 (DL3) 100 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa +CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 12 - 30 minutes, Day 7 | 4920 ng/ml |
| Phase I Dose Level 3 (DL3) 100 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa +CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 12 - PRE, C1D15, M7824 held | 14.6 ng/ml |
| Phase I Dose Level 3 (DL3) 100 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa +CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 12 - End of treatment (EOT), C2D1 | 2.13 ng/ml |
| Phase I Dose Level 3 (DL3) 100 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa +CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 10 - PRE, Day 14 | NA ng/ml |
| Phase I Dose Level 3 (DL3) 100 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa +CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 10 - 30 minutes, Day 14 | NA ng/ml |
| Phase I Dose Level 3 (DL3) 100 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa +CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 10 - 60 minutes, Day 14 | 1.28 ng/ml |
| Phase I Dose Level 3 (DL3) 100 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa +CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 10 - 120 minutes, Day 14 | 39.2 ng/ml |
| Phase I Dose Level 3 (DL3) 100 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa +CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 10 - 180 minutes, Day 14 | 155 ng/ml |
| Phase I Dose Level 3 (DL3) 100 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa +CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 10 - <6 hours (HR) of 2nd dose, Day 14 | 329 ng/ml |
| Phase I Dose Level 3 (DL3) 100 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa +CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 12 - PRE, Day 7 | 5100 ng/ml |
| Phase I Dose Level 3 (DL3) 100 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa +CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 10 - PRE, Day 7 | 991 ng/ml |
| Phase I Dose Level 3 (DL3) 100 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa +CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 10 - 30 minutes, Day 7 | 1220 ng/ml |
| Phase I Dose Level 3 (DL3) 100 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa +CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 10 - PRE, Cycle 1 Day 1 (C1D1) | 923 ng/ml |
| Phase I Dose Level 3 (DL3) 100 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa +CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 10 - End of infusion (EOI), C1D1 | 745 ng/ml |
| Phase I Dose Level 3 (DL3) 100 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa +CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 10 - PRE, Cycle 1 Day 15 (C1D15) | NA ng/ml |
| Phase I Dose Level 3 (DL3) 100 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa +CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 11 - PRE, Day 14 | NA ng/ml |
| Phase I Dose Level 3 (DL3) 100 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa +CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 11 - 30 minutes, Day 14 | 217 ng/ml |
| Phase I Dose Level 3 (DL3) 100 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa +CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 11 - 60 minutes, Day 14 | 546 ng/ml |
| Phase I Dose Level 3 (DL3) 100 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa +CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 11 - 120 minutes, Day 14 | 1090 ng/ml |
| Phase I Dose Level 3 (DL3) 100 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa +CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 11 - 180 minutes, Day 14 | 1610 ng/ml |
| Phase I Dose Level 3 (DL3) 100 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa +CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 11 - <6 hours (HR) of 2nd dose, Day 14 | 670 ng/ml |
| Phase I Dose Level 3 (DL3) 100 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa +CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 11 - PRE, Day 7 | 5140 ng/ml |
| Phase I Dose Level 3 (DL3) 100 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa +CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 11 - 30 minutes, Day 7 | 7390 ng/ml |
| Phase I Dose Level 3 (DL3) 100 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa +CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 11 - Cycle 1 Day 1 (C1D1), Treatment held | 7470 ng/ml |
| Phase I Dose Level 3 (DL3) 100 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa +CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 11 - End of treatment (EOT) | 1.53 ng/ml |
| Phase I Dose Level 3 (DL3) 100 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa +CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 12 - PRE, Day 14 | NA ng/ml |
| Phase I Dose Level 3 (DL3) 100 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa +CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 12 - 30 minutes, Day 14 | 54.7 ng/ml |
| Phase I Dose Level 3 (DL3) 100 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa +CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 12 - 60 minutes, Day 14 | 104 ng/ml |
| Phase I Dose Level 3 (DL3) 100 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa +CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 12 - 120 minutes, Day 14 | 165 ng/ml |
| Phase I Dose Level 3 (DL3) 100 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa +CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 12 - 180 minutes, Day 14 | 795 ng/ml |
| Phase I Dose Level 3 (DL3) 100 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa +CV301 | Pharmacokinetic Profile of SX-682 as a Single Agent and in Combination | Participant 12 - <6 hours (HR) of 2nd dose, Day 14 | 1380 ng/ml |
Secondary
Progression-free Survival (PFS) Using Response Evaluation Criteria in Solid Tumors (RECIST)1.1.
PFS is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first. Progression per the RECIST is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). The appearance of one or more new lesions is also considered progressions.
Time frame: Time from start of treatment to time of progression or death, whichever occurs first, approximately 10 months
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Phase I Dose Level 1(DL1) 25mg SX-682 Monotherapy Sequentially Foll/by 1200mg BinTraFusp Alfa +CV301 | Progression-free Survival (PFS) Using Response Evaluation Criteria in Solid Tumors (RECIST)1.1. | 2.0 months |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Progression-free Survival (PFS) Using Response Evaluation Criteria in Solid Tumors (RECIST)1.1. | 3.4 months |
| Phase I Dose Level 3 (DL3) 100 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa +CV301 | Progression-free Survival (PFS) Using Response Evaluation Criteria in Solid Tumors (RECIST)1.1. | 1.8 months |
Other Pre-specified
Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)
Here is the number of participants with serious and/or non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.
Time frame: Date treatment consent signed to date off study, approximately 5 months and 9 days, 13 months and 17 days, and 6 months and 1 day for DL1, DL2, and DL3 respectively. Adverse events were assessed beyond the primary completion date.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Phase I Dose Level 1(DL1) 25mg SX-682 Monotherapy Sequentially Foll/by 1200mg BinTraFusp Alfa +CV301 | Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0) | 3 Participants |
| Phase I Dose Level 2 (DL2) 50 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa + CV301 | Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0) | 6 Participants |
| Phase I Dose Level 3 (DL3) 100 mg SX-682 Sequentially Followed by 1200mg BinTraFusp Alfa +CV301 | Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0) | 3 Participants |